Cervera Deval J
Servicio de Radiología, Fundación Instituto Valenciano de Oncología, Valencia, España.
Radiologia. 2014 May-Jun;56(3):193-205. doi: 10.1016/j.rx.2012.03.010. Epub 2012 Aug 16.
Biomedical imaging makes it possible not only to diagnose and stage cancer, but also to follow up patients and evaluate the response to treatment. RECIST (Response Evaluation Criteria In Solid Tumors) provides a method to monitor the response to treatment based on one dimensional measurements of tumors obtained with reproducible imaging techniques like CT, MRI, and PET. The metabolic changes induced by new treatments modify the biology and behavior of the tumor; occasionally, there is a discrepancy between the patient's clinical condition and the response measured by RECIST, which indicates that functional tests need to be included in the evaluation of the response to treatment. The objective is to review the RECIST criteria to include the contribution of functional imaging to enable the efficacy and effects of the treatment in patients with solid tumors.
生物医学成像不仅使癌症的诊断和分期成为可能，还能对患者进行随访并评估治疗反应。实体瘤疗效评价标准（RECIST）提供了一种基于使用CT、MRI和PET等可重复成像技术获得的肿瘤一维测量来监测治疗反应的方法。新治疗方法引起的代谢变化会改变肿瘤的生物学特性和行为；偶尔，患者的临床状况与RECIST测量的反应之间存在差异，这表明在治疗反应评估中需要纳入功能测试。目的是回顾RECIST标准，纳入功能成像的贡献，以评估实体瘤患者治疗的疗效和效果。
